ERS 2019: Umeclidinium/Vilanterol Provides Early, Sustained (24 Weeks) Improvement in Symptoms of COPD at Low Risk of Exacerbations
Symptomatic benefits were apparent at week 1 and sustained over 24 weeks.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.